0 item $0.00

Vascular ageing is a key contributor to cardiovascular and cerebrovascular diseases, which collectively account for over 20 million deaths globally each year. As we age, our blood vessels progressively stiffen, losing elasticity and the ability to properly regulate blood flow. This mechanical deterioration alters the behavior of vascular cells and sets the stage for conditions such as hypertension, stroke, and heart failure. Despite its impact, there are currently no effective therapies that directly target the underlying mechanisms of arterial stiffening, due in part to the lack of models that accurately mimic human vascular ageing.

This project aims to bridge that gap by developing a fully bioengineered, human-relevant organ-on-a-chip model of vascular ageing. Our model replicates key microstructural and biomechanical changes seen in ageing vessels, including extracellular matrix (ECM) remodelling, decreased compliance, and altered hemodynamics. Using ECM derived from human cardiac tissue — chemically modified to reflect age-specific properties such as glycation, calcification, and stiffening — we are able to fine-tune the vessel wall’s characteristics in a highly controlled manner. The model also simulates arterial geometry by increasing the medial layer (containing vascular smooth muscle cells, VSMCs) and narrowing the lumen diameter, mirroring the pathological changes observed in aged arteries.

Our platform integrates advanced 3D printing and soft lithography to create customisable vascular chips in under three hours. It supports high-throughput experimentation, enabling up to 24 parallel assays with consistent mechanical properties — ideal for mechanistic studies and drug screening. A unique feature of this system is the incorporation of miniaturised sensors to monitor pressure and mechanical loading in real time, offering dynamic insight into how vascular cells respond to changes in their physical environment.

The model’s co-culture capabilities allow us to investigate how endothelial cells (VECs), VSMCs, immune cells, and ageing ECM interact under flow, stretch, and pressure. By adjusting variables such as ECM stiffness, lipid deposition, and donor age/sex, the platform can be tailored to study patient-specific responses and the role of sex differences in vascular ageing.

Through this physiologically relevant model, we aim to:

  • Uncover how mechanical cues and ageing-related ECM changes influence endothelial and immune cell function.
  • Identify key mechanotransduction pathways driving inflammation, fibrosis, and vascular dysfunction.
  • Establish a screening platform for anti-stiffening therapies and personalised intervention strategies.

This work addresses a critical need for next-generation in vitro tools that move beyond traditional 2D culture or animal models. By mimicking the complexity of human vascular ageing, our platform opens new avenues for research in mechanobiology, vascular disease, and precision therapeutics.

Media

COSMOS: How organ-on-a-chip technology is revolutionising the way we study cardiovascular disease

Key publications

 

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more